1. Wonder Vigilance

   • I. Ralph Edwards

   Editorial 19 October 2012 Pages: 83 - 86

2. Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

   • Baptist Gallwitz

   Review Article 19 October 2012 Pages: 87 - 100

   

3. Antipsychotic-Induced Hyponatraemia

   • Didier Meulendijks
   • Cyndie K. Mannesse
   • Toine C. G. Egberts

   Review Article 19 October 2012 Pages: 101 - 114

   

4. Hyperlipidaemia in Paediatric Patients

   • Anthony S. Wierzbicki
   • Adie Viljoen

   Review Article 19 October 2012 Pages: 115 - 125

5. Safety-Related Regulatory Actions for Orphan Drugs in the US and EU

   • Harald E. Heemstra
   • Thijs J. Giezen
   • Hubert G. M. Leufkens

   Short Communication 19 October 2012 Pages: 127 - 137

   

6. Prospective Data Mining of Six Products in the US FDA Adverse Event Reporting System

   • Steven Bailey
   • Ajay Singh
   • Michael Blum

   Short Communication 19 October 2012 Pages: 139 - 146

   

7. Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease

   • Jaime Kulisevsky
   • Javier Pagonabarraga

   Original Research Article 19 October 2012 Pages: 147 - 161

   

8. Comment on ’Prevalence, Incidence and Nature of Prescribing Errors in Hospital Inpatients: A Systematic Review’

   • Bryony Dean Franklin
   • Monsey McLeod
   • Nick Barber

   Correspondence 19 October 2012 Pages: 163 - 165

   

9. The Authors’ Reply

   • Penny J. Lewis
   • Tim Dornan
   • Darren M. Ashcroft

   Correspondence 19 October 2012 Pages: 165 - 166

10. Drug Form and Expression of Concentration May also Lead to Prescription Errors

    • Vaithianadan Mani
    • Daniel W. Wheeler

    Correspondence 19 October 2012 Pages: 167 - 168

11. The Authors’ Reply

    • Mary P. Tully
    • Darren M. Ashcroft
    • Val Wass

    Correspondence 19 October 2012 Pages: 168 - 169